Chapter
The Ethics of Drug Pricing and Regulation
13:17 - 20:25 (07:08)
The high cost of drugs for diseases like Alzheimer's highlights the regulatory mess in the healthcare industry, where pharmaceutical companies charge whatever they want for drugs to make profit, and regulators have to balance accessibility with affordability while ensuring drug efficacy.
Clips
The high cost of Alzheimer's drugs raises questions about healthcare regulations, costs and price gouging.
13:17 - 17:13 (03:56)
Summary
The high cost of Alzheimer's drugs raises questions about healthcare regulations, costs and price gouging. Medicare Part B, a regulatory body that covers healthcare expenses, is meant to give physicians the knowledge to make informed decisions about the drugs they recommend to patients, but it also rewards them with a 6% kickback of the drug's price, further inflating the cost of drugs.
ChapterThe Ethics of Drug Pricing and Regulation
EpisodeE35: Biogen's controversial Alzheimer's drug approval, the billionaire space race, real estate, Bitcoin & more
PodcastAll-In with Chamath, Jason, Sacks & Friedberg
The debate on whether the FDA should approve drugs for terminal prognoses is tricky as the evidence for treatments like Alzheimer's is often inconclusive.
17:13 - 18:49 (01:35)
Summary
The debate on whether the FDA should approve drugs for terminal prognoses is tricky as the evidence for treatments like Alzheimer's is often inconclusive. There is a call for certain drugs to be more easily approved to provide those facing terminal diseases the ability to try them.
ChapterThe Ethics of Drug Pricing and Regulation
EpisodeE35: Biogen's controversial Alzheimer's drug approval, the billionaire space race, real estate, Bitcoin & more
PodcastAll-In with Chamath, Jason, Sacks & Friedberg
Drug pricing is based on the long-term cost benefit of the drug to the paying system rather than the actual cost of producing the drug.
18:49 - 20:25 (01:35)
Summary
Drug pricing is based on the long-term cost benefit of the drug to the paying system rather than the actual cost of producing the drug.